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OBJECTIVES: Diabetes mellitus is responsible for a huge burden of disease. Our 
objective was to estimate the direct health-care costs of patients with diabetes in 
Hungary. METHODS: Real-world data were retreived from the National Health 
Insurance Fund database. Diabetic patients were deﬁ ned as persons who ﬁ lled in a 
prescription of oral antidiabetics (OAD) or insulin in Q3-Q4 2007. Study population 
was divided into two groups depending on whether they were hospitalized for major 
complications of diabetes in 2007–2008. Patients without hospitalization were further 
divided into three subgroups according to the use of drugs (only OAD, only insulin, 
OAD and insulin). In all subgroups, we estimated health-care costs for each cost item 
by age group in the whole study group and among those who actually used a particular 
service. Additionally, we took samples of patients who were hospitalized for speciﬁ c 
complications, and estimated health-care costs for the ﬁ rst and second year after the 
occurrence of the complication. Hungarian Forint values were converted to Euros by 
employing the 2008 GDP speciﬁ c PPP exchange rate (1c = 157.64HUF). RESULTS: 
Mean health-care cost of 521,545 diabetic patients was c2125 in 2008. It was c4016 
for those with hospitalization for complications, c1533 for OAD users without com-
plications, and c2847 for insulin users without complications. Fifty-three percent of 
the total cost covered drug treatment and 27% acute hospital treatment; 26% of the 
total drug cost was spent on OADs and on insulin. CONCLUSIONS: Health-care cost 
of diabetes is already high in Hungary, especially care for its complications. Public 
health-care cost of diabetes exceeds 0.65% of GDP and 13% of total direct public 
health-care expenditure. Considering the burden of disease that manifests in premature 
mortality, reduction in QoL, and high cost, and the epidemiological trends, diabetes 
mellitus should be a public health priority in Hungary.
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BACKGROUND: Recent research suggests that direct medical costs and quality of 
life in diabetes depends on number of diabetes-related complications. OBJECTIVES: 
To analyze relationships of quality of life and medical costs with clinical characteristics 
of diabetes mellitus patients. METHODS: A retrospective longitudinal cost of care 
study was conducted; type 1 and 2 diabetic patients accessing at two hospitals in the 
north-east area of Italy were recruited between October 2008 and March 2009. At 
enrollment data on demographic, clinical status and QoL (EQ-5D) were collected. 
Information on costs occurring during the previous 2 years was obtained from a chart 
review: hospitalizations, specialist medical visits, diagnostic examinations, drugs, and 
the main clinical parameters. Costs were quantiﬁ ed from the National Health Service 
(NHS), by applying tariffs and prices valid in 2009. Data were analyzed with a mul-
tivariable linear regression model. RESULTS: A total of 411 valid patients (mean + 
SD age = 64.1 + 12.7, 56.5% male) were enrolled: 15.9% had type 1, 83.4% type 2 
diabetes, and 0.7% had other type of diabetes. Costs were on average c234.36/patient-
month; hospitalization accounted for the greatest proportion of costs (58.5%), fol-
lowed by pharmacological therapies (32.6%) and diagnostic exams (8.9%). With 
EQ-5D: VAS was on average + SD = 67.74 ± 16.71. Both Costs and HRQoL showed 
a linear-positive (costs) and -negative (HRQoL) relationship with number of diabetes-
related complications (diabetic retinopathy, diabetic nephropathy, diabetic neuropa-
thy, ischemic cardiopathy, vascular diseases, and diabetic foot), adjusting for age and 
gender and type of diabetes. On the contrast, no relationship was found with type of 
complications. CONCLUSIONS: Long-term complications carry a considerable 
impact on medical cost and HRQoL. Although apparently costly, strategies aimed to 
optimize the prevention of the onset of diabetic complications should be considered 
as a potential investment to gain health and reduce costs in the long run.
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OBJECTIVES: The painful diabetic peripheral neuropathy (DPN) is the most common 
complication of diabetes. Despite the prevalence of painful DPN and its potential risk 
of foot ulcer and amputation, there has been no study about painful DPN on economic 
burden in Korea. This study was conducted to assess the patient-level economic burden 
among subjects with painful DPN. METHODS: A cross-sectional multicenter study 
was performed using a standardized questionnaire, to estimate recent 3-month health-
care and non-health-care cost, and productivity loss of diabetic patients. a total of 
4000 patients were recruited from 40 hospitals between December 2009 and May 
2010. Cost items mainly included health-care cost such as outpatient, pharmacy, 
inpatient, and oriental medicine; non-health-care cost such as trafﬁ c expenses, nursing 
cost, complementary, and alternative medicine. Cost included insurance-covered cost 
as well as patient’s out-of-pocket expenses during 3 months. To estimate productivity 
loss due to morbidity, days away from work due to painful DPN were also investi-
gated. RESULTS: Among 2681 diabetic patients completed questionnaire (response 
rate = 67.0 %), 26.3% (n = 706) had painful DPN. Numbers of outpatient visit within 
3 months were higher in patients with painful DPN compared to those in patients 
without painful DPN, 3.79 ± 2.83 and 3.25 ± 2.36, respectively (P < 0.01). Total costs 
over 3 months were also higher in patients with painful DPN than in those without 
painful DPN (1,049,477 ± 1,549,446 and 721,933 ± 1,394,970 KRW, respectively, 
P < 0.01); Median costs were higher among patients with painful DPN (656,585 vs. 
421,668 KRW). Within 3 months, 8.2% and 43.5% of patients with painful DPN 
had been away from work and reported the decreased work productivity, respectively. 
CONCLUSIONS: Painful DPN increased health-care cost and decreased work pro-
ductivity of diabetic patients in Korea.
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OBJECTIVES: As in so many other countries, diabetes is one of the largest health 
problems faced by Portugal. Up to now, there have been no “cost of illness” studies for 
diabetes in Portugal. This paper provides a contribution to ﬁ ll that gap by estimating 
the indirect costs of illness, more speciﬁ cally the output loss due to short- and long-term 
disability attributable to diabetes in Portugal. METHODS: The estimates are based on 
the microdata of the 4th National Health Survey conducted in 2005/2006. An employ-
ment logit is estimated with covariates including age, gender, education levels, and 
regional dummies as well as a dummy for diabetes and dummies for other relevant 
health conditions for all people in the survey with ages between 20 and 74. a comparison 
of the baseline labor market participation/employment estimates and model predictions 
assuming zero diabetes prevalence provides the estimates for the labor market impact 
of diabetes. The estimates are speciﬁ ed by age groups and gender. At this point, the 
analysis uses microdata from the Labor Ministry, covering about 3 million workers, to 
estimate gross wages and employer Social Security contributions by age and gender, 
allowing us to use the human capital approach to put a value on the diabetes-induced 
labor market nonparticipation. RESULTS: The nonemployment estimates generated by 
the logit-based methodology are that diabetes reduces employment by 22,150 in a 4.6 
million demographic group. The corresponding output loss is estimated to have been 
c324 million. CONCLUSIONS: The output loss is one of the main costs of diabetes in 
Portugal. Its amount is four times larger than the available estimates for diabetes’ 
attributable inpatient care in National Health Service hospitals.
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OBJECTIVES: Diabetes is one of that chronic diseases in which the increase of the costs 
cause ﬁ nancial problems for the National Health Insurance Fund in Hungary. Aim of 
the study is the examination of it in a 5-year period from 2003 to 2008. METHODS: 
The number of diabetic patients, the type of treatment services, the ﬁ nancial support, 
and the costs were analyzed. Data were derived from the National Health Insurance 
Fund Administration. RESULTS: Measuring by the medical ID, the numbers of patient 
increased by 34% during 5 years. The numbers of case increased in the outpatient 
services by 14% (from 213,790 to 243,960). The numbers of the hospital treatment day 
decreased by 5% (3,342,857; 3,168,263) The day off work due to sickness and the cost 
of it increased by 345% (from 8275c to 36,860c). While ﬁ nancial support of devices 
for the measurement of blood sugar increased by 93% c4900 to c9400 and support of 
insulin treatment increased 111%, than the increase of the number of insulin-treated 
patients was only 46%, 91,920 (2003) and 134,617 (2008). Similarities were seen in 
numbers (40%) and in costs (94%) in the noninsulin-treated patients from 195,662 to 
274,886 and from c7900 to c15,300. The total change in ﬁ nancial support was 72%. 
CONCLUSIONS: Increase in the number of diabetic patients was seen during this 5-year 
period. The increase of the number in outpatient services was higher than in inpatient 
services. The decrease in numbers of hospital bed could explain it. The economic crisis 
could cause the growing in the numbers of day off work. The increase in the medical 
ﬁ nancial support compared to the number of patients had to be mentioned, because it 
could be caused by enhancement in the administration of the innovative medical prod-
ucts. Basic strategy should be found against health cost explosion.
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OBJECTIVES: Despite the rapid development of pharmacoeconomics and outcomes 
research in new countries joining European Union (EU), there is still scarcity of cost 
of illness studies compared to old EU members. The aim of the study was to review 
all studies concerning costs of diabetes type 1 and 2 and its complications in old and 
new EU members. The following countries were taken into account: Slovenia, Poland, 
Czech Republic, Hungary, Slovakia, Bulgaria, Romania, Lithuania, Latvia, and 
